A new Beam Expanding Access to Superior Radiotherapy and Radiosurgery
overview: Convergent R.N.R (CRNR) developed a transformational AI driven robotic radiation platform that was exclusively designed to significantly reduce non-therapeutic dose to adjacent critical structures, disrupting a stagnant radiation therapy/surgery equipment market. The uniquely converging low energy x-ray beam fulfils the un-met proton beam therapy promise, for a less toxic (to nearby organs) radiation solution, at a fraction of the cost, while reducing total cost of ownership by eliminating the need for a concrete bunker.
Corporate ID
CRnR’s unique beam structure produces a Photon Spread Out Peak (PSOP) effect which closely replicates the effects of the Proton SOBP with a region of maximum dose at the target and a reduced dose before and after the target.
CRNR’s ANGELCURE ™ Beam Shape
Competitive advantages:
The system offers the following benefits when compared with virtually all radiation therapy and radiation surgery tools on the market today:
Safer treatment: Superior (reduced) dose to neighbouring tissue thanks to the Bragg Peak Like profile of the focused x-ray photon beam. See Isodose comparison in sample lung case below, showing reduced radiation to the heart, lung and liver vs Linac.
Better value to all stake holders: Our radiation source is essentially a CT tube (KeV range), enabling a higher operational gross margin to us as manufacturer and much lower total cost of ownership to our customers- as there is no need to for high density concrete and steel bunker and about $1 million in infrastructure expenses.
Better aligned with future of oncology: Demonstrated 20% higher RBE (Relative Biology Efficiency) with potential ability to narrow the ITV-PTV gap, thus highly synergetic with RT+Immuno-therapies combo.
Access: Enabling the migration of radio therapy and radio surgery beyond the urban hospital to communities which previously lacked access as well as to mobile platforms reaching underserved patient populations via lower-cost non-hospital and outpatient locations.
Lung Tumor- case 2.1
Isodose comparison
Clinical Long term partnership with MD Anderson Cancer Center (MDACC) and more recently with Brigham & Woman’s (Boston).
IP A robust portfolio of Eleven patent families filed (25 sub-families patents in total)
Market Current market of 1500 large urban hospitals represents a $5B market, with an opportunity of an additional 5000 underserved remote/rural clinics representing an additional $4B market.
Pipeline Incisionless denervation and ablation opportunities represent an additional market opportunity of $100B.
Management Team
Gil Rosen CEO
Mike Cogswell VP Business Development
Ron Goldwasser COO
Eyal Glotman VP R&D
Medical Advisory Board
Dr. Stephan Hahn Former Head of FDA, Chairman Medical Advisory Board
Dr. Achy Yahalom Memorial Sloan Kettering Cancer Center (MSKCC)
Dr. Caroline Chung MD Anderson Cancer Center (MDACC)
Prof. Eyal Fenig Davidoff Cancer Center Rabin Medical Center (RMDCC)